Welcome : Guest

Alnylam Pharmaceuticals, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Alnylam Pharmaceuticals, Inc., which is principally involved in Biopharmaceuticals Business. Illustrated with 101 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-07161
Price: $3500
Company Type: Public
Pages: 103
Date: November 2016
Market Data Tables: 101

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Speciality Pharmaceuticals......3
Table 1: New Pharmaceutical Licensed Drugs Market by Indication Worldwide (2015) - Percentage Share Breakdown by Value Sales for AIDS, Diabetes, Diabetes (DPP4), Hepatitis B, Hypertension, and Others......3
Table 2: Speciality Drug Sales by Therapeutic Category in the US (2015) - Percentage Market Share Breakdown by Value for Anticoagulants, Cancer, Growth Deficiency, Hepatitis C, HIV, Inflammatory Conditions, Multiple Sclerosis, Pulmonary Hypertension, Respiratory Conditions, Transplant and Others......4
Table 3: Speciality Pharmaceuticals Market by Category in the US (2015) - Percentage Share Breakdown by Value Sales for Anti-Coagulant, Growth Hormone, Hepatitis C, HIV/AIDS (incl oral solids), IVIG/Hemophilia, Macular Degeneration, Multiple Sclerosis, Oncology (incl. oral solids), Pulmonary Arterial Hypertension, Renal, Rheumatoid arthritis/Chrohn's, Transplant, and Others......5
Cardiology Therapeutics......6
Table 4: Cardiovascular Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for ACE Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, Anti-Arrhythmics, Anti-Thrombotics, Beta Blockers, Calcium Channel Blockers, Cholesterol, GP IIb/IIIa Inhibitors, Vasodilators, and Others......6
Table 5: Cardiology Market by Category in the US (2015) - Percentage Breakdown by Value Sales for ACE Inhibitors, Alpha Blockers, Anti-Arrhythmics, ARB's, Beta Blockers, Calcium Blockers, Cholesterol, Digitalis, Diuretics, Vasodilators, and Others......7
Table 6: Cardiology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Cardiac Rhythm Management & Congestive Heart Failure Devices, Cardiac Surgery, and Interventional Cardiology......8
Diabetes......9
Table 7: Diabetes Market by Region Worldwide (2015) - Percentage Share Breakdown for Africa, Europe, Middle East & North Africa, North America & Caribbean, Southeast Asia, and Western Pacific......9
Table 8: Diabetes Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Insulin Type-1 Diabetes, Insulin Type-2 Diabetes, Dipeptidyl Peptidase 4, (DPP4), Glucagon-like Peptide-1 (GLP-1), Dipeptidyl Peptidase 4, (DPP4) + Biguanide, and Others* (includes Sodium-Glucose Co-Transporter-2 (SGLT2), Biguanide, Sulfonylurea, Alpha-Glucosidase Inhibitors, Peroxisome Proliferator-Activated Receptor (PPAR)......10
Table 9: Diabetes Care Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Human Insulins, Modern Insulins, Victoza, and Others......11
Table 10: Type-II Diabetes Treatments Market Worldwide (2015-2020) in US$ Million......12
Table 11: Type II Diabetes Market by Treatment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-IV Inhibitors, GLP-1 Agonists, SGLT-2 Inhibitors and Thiazolidinediones......13
Table 12: Type II Diabetes Market by Insulin Treatment Worldwide (2015) - Percentage Share Breakdown by Value for Diet and Exercise Only, Insulin and Orals and Insulin Only......14
Table 13: Diabetes Healthcare Market by Category in the US (2015) - Percentage Share Breakdown by Value for Anti -Diabetic Agents & Supplies, Doctor Office Visits, Hospital Care, Nursing/Residential Facility Stays, Prescription Medication, and Others......15
Table 14: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown for Insulin Pumps, and Multiple Daily Injections......16
Table 15: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown by Value for Type 1, and Type 2......17
Table 16: No. of Diabetes Patients by Medication in the US (2015) - Percentage Share Breakdown for Insulin and Oral Medication, Insulin Only, No Medication, and Oral Medication Only......18
Diabetes Drugs......19
Table 17: Diabetes Drug Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-4 Inhibitor, GK Activator, GLP-1 Agonist, GPCR Agonist, IL- Receptor Antagonist, Insulin Analogue, PPAR Agonist, SGLT-2 Inhibitor, and Others......19
Table 18: Diabetes/Metabolic Drugs Market by Category Worldwide (2015) - Percentage Breakdown by Value Sales for DPP-IV Inhibitors, Glitazones, GLP-1 Analogs, Insulins, Sulfonylureas, and Others......20
Table 19: Anti-Diabetic Drug Market by Treatment Class Worldwide (2015) - Percentage Share Breakdown by Value for Diet & Exercise, Incretion, Insulin and Oral Anti-Diabetic......21
Table 20: Antidiabetes Molecules Market by Drug Worldwide (2015) - Percentage Share Breakdown by Value for Metformin, Sulfonylureas, Thiazolidin Ediones and Others......22
Table 21: Anti-Diabetic Drugs Market in China (2015-2020) in RMB Million......23
Table 22: Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glinide, Insulin, Sulfonylureas, α-glucosidase Inhibitor, and Others......24
Table 23: Anti-Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Insulin Drugs and Non-Insulin Drugs......25
Table 24: Diabetes Drugs Market by Product Category in China (2015) - Percentage Share Breakdown by Value for Acarbose, Insulin, Melbine, and Other Diabetes Drugs......26
Table 25: Diabetic Drugs Market by Category in the US (2015) - Percentage Share Breakdown by Value for DPP-IV & SGLT-2, GLP-1, Insulins, and Others......27
Table 26: Diabetic Drugs Market by Non-Insulin Therapy in the US (2015) - Percentage Share Breakdown by Volume for Biguanides, DPP-4 Inhibitor, Human GLP-1 Analogs, SGLT-2 Inhibitor, Sulfonylureas, and Others......28
Table 27: Oral Diabetes Medicine Market in the US (2015) - Percentage Share Breakdown by Value Sales for Dipeptidyl Peptidase-4 (DPP4), Metformin, Sulfonylureas, and Others......29
Non-Insulin Anti-Diabetic Drugs......30
Table 28: Non-Insulin Anti-Diabetic Drugs Market by Product in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glucosidase Inhibitors, Nateglinide, Sulfonylurea and Others......30
Diabetic Macular Edema (DME)......31
Table 29: Diabetic Macular Edema (DME) Market by Drug Treatment Worldwide (2015) - Percentage Share Breakdown by Volume for Avastin, Laser Photocoagulation, Lucentis 0.3 mg, Steroids and Others......31
Table 30: Diabetic Macular Edema (DME) Anti Vascular Endothelial Growth Factor (VEGF) Market by Segment in the US (2015) - Percentage Share Breakdown by Volume for Avastin, Lucentis and Others......32
Insulin......33
Table 31: Insulin Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Aspart (Novolog), Detemir (Levemir), Glargine (Lantus), Glulisine (Apidra), Lispro (Humalog), and Rh Insulin......33
Table 32: Insulin Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Basal Insulins, Prandial Insulins and Pre-Mixed Insulin......34
Table 33: Insulin Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Fast Acting, Long Acting and Premix......35
Table 34: Insulin Market by Generation in China (2015) - Percentage Share Breakdown by Value for 1st Generation, 2nd Generation, and 3rd Generation......36
Table 35: Insulin Market by Product Type in the US (2015) - Percentage Share Breakdown by Value for Fast-Acting, Human, Long-Acting and Mix......37
DPP-4 Inhibitors......38
Table 36: DPP-4 Inhibitors Market by Product Category Worldwide (2015) - Percentage Share Breakdown by Value for Galvus & Galvumet (Novartis), Januvia & Janumet (MRK), Nesina & Kezano (Takeda), Onglyza & Kombiglyze (AZN/BMY) and Tradjenta & Jentadueto (BI/Lilly)......38
Table 37: DPP-4 Inhibitors Market in China (2015-2020) in RMB Million......39
Table 38: DPP-4 Inhibitors (Fixed Dose) Market by Product Category in Korea (2015) - Percentage Share Breakdown by Value for Galvusmet, Janumet, Janumet XR, Kombiglyze, Trajenta Duo and Zemimet......40
Table 39: DPP-4 Inhibitors (Non-fixed Dose) Market by Product Category in Korea (2015) - Percentage Share Breakdown by Value for Januvia, Nesina, Tradjenta, Zemiglo, and Others......41
Table 40: DPP-4 Inhibitors Market by Prescription in the US (2015) - Percentage Share Breakdown by Volume for Janumet (Sitagliptin + Metformin), Januvia (Sitagliptin), Kombiglyze XR (Saxagliptin + Metformin), Onglyza (Saxagliptin), and Others......42
Table 41: DPP-4 Inhibitors Market in the US (2015) in No. of Prescriptions......43
DPP-4 type Diabetes Drugs......44
Table 42: DPP-4 type Diabetes Drugs Market in Japan (2015) in Yen Million......44
Hemophilia......45
Table 43: Hemophilia Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Hemophilia A, Hemophilia B, Inhibitor, and Von Willebrand Disease......45
Table 44: Hemophilia Diagnosis and Treatments Rates by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for Diagonised, Pristine Joints, Prophylactic, Treated, and Others......46
Table 45: Haemophilia by Severity Stage Worldwide (2015) - Percentage Market Share Breakdown by No. of Patients for Mild, Moderate and Severe......47
Table 46: Haemophilia Patient Population by Category Worldwide (2015) - Percentage Market Share Breakdown by Volume for Haemophilia A (Factor VIII Deficiency) and Haemophilia B (Factor IX Deficiency)......48
Table 47: Continuous Prophylaxis (Moderate) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......49
Table 48: Continuous Prophylaxis Treatment (Severe) for Hemophilia A Patients by Age Group Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......50
Table 49: On-Demand (Moderate Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......51
Table 50: On-Demand (Severe Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......52
Table 51: Haemophilia B - Recombinant (Benefix) Sales by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Emerging Markets, Europe, US, and Others......53
Table 52: Immune Tolerance Therapy (Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......54
Table 53: Intermittent Prophylaxis (Moderate Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......55
Table 54: Intermittent Prophylaxis (Severe Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......56
Table 55: U.S. Hemophilia Market Patients Treated/Year (2014)......57
Hepatitis B......58
Table 56: No. of Hepatitis B Patients by Region in Europe (2015) - Percentage Market Share Breakdown by Volume for Eastern Europe, and Western Europe......58
Table 57: No. of Hepatitis B Patients by Country in Eastern Europe (2015) - Percentage Market Share Breakdown by Volume for Hungary, Poland, and Romania......59
Table 58: No. of Hepatitis B Patients by Country in West Europe (2015) - Percentage Market Share Breakdown by Volume for France, Germany, Italy, Netherlands, Spain, United Kingdom, and Others......60
Pulmonary Arterial Hypertension (PAH)......61
Table 59: Pulmonary Arterial Hypertension (PAH) Treatment by Drug Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Adcirca, Letairis/Volibris, Remodulin, Revatio, Tracleer, Tyvaso and Ventavis......61
Table 60: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy Worldwide (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......62
Table 61: Pulmonary Arterial Hypertension (PAH) Treatment with Macitentan Drug by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Japan, US and Rest of World......63
Table 62: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......64
Table 63: Pulmonary Arterial Hypertension (PAH) Treatment by Type Worldwide (2015) - Percentage Breakdown by Value for Inhaled Prostacyclins, Orals (ERAs, PDE5s, Prostacyclins), and Parenteral Prostacyclins......65
Table 64: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type in Europe (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......66
Table 65: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy in Europe (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......67
Table 66: Pulmonary Arterial Hypertension Treatment Market by Product Segment in Japan (2015) - Percentage Share Breakdown by Value for Adcirca, Dorner, Flolan, Procylin, Revatio, and Tracleer......68
Table 67: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy in the US (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......69
Table 68: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type in the US (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......70
Alpha 1-antitrypsin (AAT)......71
Table 69: Alpha 1-antitrypsin (AAT) Market by Product Segment Worldwide (2015) - Percentage Share Breakdown by Value for Aralast NP, Glassia IV, Prolastin Prolastin C, and Zemaira......71
Amyloidosis......72
Table 70: Amyloidosis Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for AA, AL and ATTR......72
Cardiology Therapeutics......73
Table 71: Market Shares of Leading Cardiology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......73
Diabetes Drugs......74
Table 72: Market Shares of Leading Diabetes Care Companies Worldwide (2014) - Percentage Breakdown by Value Sales for Bristol-Myers Squibb (Incl Amylin), Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi S.A. and Others......74
Table 73: Market Shares of Leading Diabetes Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., and Others......75
Table 74: Market Shares of Leading Anti-Diabetic Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Abbott Healthcare Pvt Ltd., Biocon Limited, Lupin Pharmaceuticals, Inc., MSD Pharmaceuticals Private Limited, Sanofi-Aventis Groupe, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., and Others......76
Insulin......77
Table 75: Market Shares of Leading Insulin Companies Worldwide (2014) - Percentage Breakdown by Value Sales for Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., and Others......77
Table 76: Market Shares of Leading Insulin Companies Worldwide (2014) - Percentage Breakdown by Volume Sales for Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., and Others......78
Table 77: Market Shares of Leading Fast & Intermediate Type Insulin Producers Worldwide (2015) - Percentage Share Breakdown by Value for Eli Lilly and Company, Novo Nordisk, Sanofi S.A. and Others......79
Table 78: Market Shares of Leading Long-Acting Insulin Producing Companies Worldwide (2015) - Percentage Share Breakdown by Value for Sanofi S.A., Wockhardt Ltd., and Others......80
Table 79: Market Shares of Leading Insulin Companies in China (2014) - Percentage Share Breakdown by Value for Eli Lilly and Company, GanLee Pharmaceutical Co., Ltd., Novo Nordisk, Sanofi S.A., Shanghai Fosun Pharmaceutical Group Co., Ltd., United Laboratories International Holdings Ltd. (The), Tonghua Dongbao Pharmaceutical Co., Ltd., and Others......81
Table 80: Market Shares of Leading Insulin Companies in China (2015) - Percentage Share Breakdown by Volume for Novo Nordisk, Tonghua Dongbao Pharmaceutical Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Others......82
Table 81: Market Shares of Leading Insulin Companies in Europe (2014) - Percentage Breakdown by Volume Sales for Novo Nordisk A/S, and Others......83
Table 82: Market Shares of Leading Insulin Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Biocon Ltd., Cadila Pharmaceuticals Ltd., Eli Lilly and Company India Pvt. Ltd., Lupin Pharmaceuticals, Inc., Novo Nordisk India Ltd., Pfizer India Ltd., Ranbaxy Laboratories Ltd., Sanofi India Ltd., Shreya Life Sciences Pvt. Ltd., USV Ltd., and Wockhardt Ltd.......84
Table 83: Market Shares of Leading Insulin Companies in Japan and Korea (2014) - Percentage Breakdown by Volume Sales for Novo Nordisk A/S, and Others......85
Table 84: Market Shares of Leading Insulin Companies in North America (2014) - Percentage Breakdown by Volume Sales for Novo Nordisk A/S, and Others......86
Second-Generation Insulin......87
Table 85: Market Shares of Leading Second-Generation Insulin Companies in China (2014) - Percentage Share Breakdown by Volume for Eli Lilly and Company, Novo Nordisk, The United Laboratories International Holdings, Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd.......87
Third-Generation Insulin......88
Table 86: Market Shares of Leading Third-Generation Insulin Companies in China (2014) - Percentage Share Breakdown by Volume for Eli Lilly and Company, Gan & Lee Pharmaceutical, Ltd., Novo Nordisk, and Sanofi S.A.......88
Human Insulin......89
Table 87: Market Shares of Leading Human Insulin Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Biocon Limited, Eli Lilly and Company India Pvt. Ltd., Novo Nordisk India Limited, Sanofi India Limited, Wockhardt Ltd., and Others......89
DPP-4 Inhibitors......90
Table 88: Market Shares of Leading DPP-4 Inhibitors Manufacturers by Value Sales Worldwide (2015) - Percentage Share Breakdown for Merck & Co., Inc. (Januvia/Janumet), Novartis AG (Galvus/Galvumet) and Takeda Pharmaceutical Co., Ltd. (Nesina/Kezano), and Others......90
Table 89: Market Shares of Leading DPP-4 Inhibitors for Treatment of Diabetes in Japan (2015) - Percentage Share Breakdown by Value for Equa, Glactiv, Januvia, Nesina, and Others......91
Table 90: Market Shares of Leading DPP-4 Drug Brands in China (2015) - Percentage Share Breakdown by Value for Galvus, Januvia, Onglyza, and Others......92
Sitagliptin/Metformin......93
Table 91: Market Shares of Leading Sitagliptin Brands by Value Sales in India (2015) - Percentage Share Breakdown for Istavel and Januvia......93
Table 92: Market Shares of Leading Sitagliptin Manufacturers by Value Sales in India (2015) - Percentage Share Breakdown for Merck & Co., Inc. and Sun Pharmaceutical Industries Ltd.......94
Table 93: Market Shares of Leading Sitagliptin/Metformin Brands by Value Sales in India (2015) - Percentage Share Breakdown for Janumet, and Others......95
Table 94: Market Shares of Leading Sitagliptin/Metformin Manufacturers by Value Sales in India (2015) - Percentage Share Breakdown for Merck & Co., Inc., and Others......96
Metformin......97
Table 95: Market Shares of Leading Metformin Suppliers in India (2015) - Percentage Share Breakdown by Value for Harman Finochem Ltd., USV Pharmaceuticals Ltd., Wanbury Limited and Others......97
Hepatitis B Drugs......98
Table 96: Market Shares of Leading Hepatitis B Drug Manufacturers by Value Sales in Korea (2014) - Percentage Breakdown for Bemis Company, Inc. (BMS), Bukwang Pharmaceutical Co., Ltd (Levovir), GlaxoSmithKline Plc (Hopsera, Zeffix), Novartis International AG (Sebivo), and Others......98
Table 97: Market Shares of Leading Hepatitis B Drug Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Bemis Company, Inc.(Baraclude), F. Hoffmann-La Roche AG (Pegasys), GlaxoSmithKline Plc (Hepsera, Zeffix), and Novartis International AG (Sebivo)......99
Alpha 1-Antitrypsin (AAT)......100
Table 98: Market Shares of Leading Alpha 1-Antitrypsin (AAT) Producers Worldwide (2015) - Percentage Breakdown by Volume for Baxter International, Inc., CSL Ltd., Grifols, S.A., and Others......100
Hypertriglyceridemia......101
Table 99: Market Shares of Leading Prescription Drugs for the Treatment of Hypertriglyceridemia in the US (2015) - Percentage Share Breakdown by Volume for Lovaza, Niaspan & Advicor, Trilipix, Vascepa, and Others......101
Table 100: Market Shares of Leading Prescription Drugs for the Treatment of Severe Hypertriglyceridemia in the US (2015) - Percentage Share Breakdown by Value for EpanoVa, Lovaza, Trilipix, Vascepa, and Others......102
Table 101: Alnylam Pharmaceuticals, Inc.’s Sales by Business Segment Worldwide (2013) in Percentage for Takeda, Cubist, Monsanto, MDCO, and Others......103